Story perspectives

Kennedy Backs Peptides Amid Safety Concerns and FDA Change

4/7/2026

Summary

Story summary

Robert F. Kennedy Jr. supports the use of experimental peptides despite public health concerns about safety and efficacy.
He says the FDA will reclassify 14 peptides to improve access, reversing a 2023 rule.
Critics warn of risks, including cancer, as peptide popularity rises from social media influencers and self-experimentation.
Experts caution that research on these drugs is insufficient, and the FDA faces pressure to balance innovation with safety regulations.

1 of 1

Story summary

Robert F. Kennedy Jr. supports the use of experimental peptides despite public health concerns about safety and efficacy.
He says the FDA will reclassify 14 peptides to improve access, reversing a 2023 rule.
Critics warn of risks, including cancer, as peptide popularity rises from social media influencers and self-experimentation.
Experts caution that research on these drugs is insufficient, and the FDA faces pressure to balance innovation with safety regulations.